15:37 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

EU approval for alofisel to treat perianal fistulas

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said the European Commission approved an MAA for Alofisel darvadstrocel to treat complex perianal fistulas in patients with Crohn's disease. The companies said Alofisel is...
18:23 , Jan 12, 2018 |  BC Week In Review  |  Company News

Takeda acquiring TiGenix for €520M

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will acquire TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) for €1.78 per share in cash, or €520 million ($617.6 million). The price is an 82% premium to TiGenix’ close of €0.98...
21:11 , Jan 5, 2018 |  BC Extra  |  Company News

Takeda acquiring TiGenix for €520M

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Friday it will acquire TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) for €1.78 per share in cash, or €520 million ($617.6 million). The price is an 82% premium to TiGenix’ close of...
20:23 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

TiGenix to discontinue cardiovascular pipeline

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said it will discontinue development of its allogeneic cardiovascular stem cell program, including AlloCSC-01, to focus on candidates derived from its expanded adipose-derived stem cell (eASC) platform, including Alofisel darvadstrocel (Cx601)...
00:14 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

CHMP backs TiGenix's Alofisel for Crohn's

EMA's CHMP recommended approval of Alofisel darvadstrocel (Cx601) from TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat complex perianal fistulas in patients with Crohn’s disease. In 2016, TiGenix granted Takeda exclusive...
23:22 , Dec 15, 2017 |  BC Extra  |  Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer...
19:45 , Jul 5, 2017 |  BC Week In Review  |  Clinical News

TiGenix starts Phase III ADMIRE-CD II trial of Cx601

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) began the Phase III ADMIRE-CD II trial of Cx601 to treat complex perianal fistulas in patients with Crohn’s disease (CD). The double-blind, placebo-controlled, international trial is evaluating the combined remission of...
12:50 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Cx601 regulatory update

FDA agreed to a shortened Phase III trial design for Cx601 to treat perianal fistulas in patients with Crohn's disease (CD) that would allow the company to submit a BLA for the product a year...
23:22 , Mar 7, 2017 |  BC Extra  |  Clinical News

TiGenix speeds Cx601 timeline

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said FDA agreed to a shortened Phase III trial design that would allow the company to submit a BLA for Cx601 one year earlier than originally planned. The study is evaluating...
23:59 , Dec 15, 2016 |  BC Extra  |  Financial News

TiGenix raises $35.7 million in NASDAQ listing

Cell therapy company TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) raised $35.7 million through the sale of 2.3 million ADSs at $15.50 in a listing on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Each...